FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039084800> ?p ?o ?g. }

• W2039084800 endingPage "434" @default.
• W2039084800 startingPage "429" @default.
• W2039084800 abstract "A phase I clinical trial was conducted to determine the clinical safety of Telomelysin, a human telomerase reverse transcriptase (hTERT) promoter driven modified oncolytic adenovirus, in patients with advanced solid tumors. A single intratumoral injection (IT) of Telomelysin was administered to three cohorts of patients (1 × 1010, 1 × 1011, 1 × 1012 viral particles). Safety, response and pharmacodynamics were evaluated. Sixteen patients with a variety of solid tumors were enrolled. IT of Telomelysin was well tolerated at all dose levels. Common grade 1 and 2 toxicities included injection site reactions (pain, induration) and systemic reactions (fever, chills). hTERT expression was demonstrated at biopsy in 9 of 12 patients. Viral DNA was transiently detected in plasma in 13 of 16 patients. Viral DNA was detectable in four patients in plasma or sputum at day 7 and 14 post-treatment despite below detectable levels at 24 h, suggesting viral replication. One patient had a partial response of the injected malignant lesion. Seven patients fulfilled Response Evaluation Criteria in Solid Tumors (RECIST) definition for stable disease at day 56 after treatment. Telomelysin was well tolerated. Evidence of antitumor activity was suggested. A phase I clinical trial was conducted to determine the clinical safety of Telomelysin, a human telomerase reverse transcriptase (hTERT) promoter driven modified oncolytic adenovirus, in patients with advanced solid tumors. A single intratumoral injection (IT) of Telomelysin was administered to three cohorts of patients (1 × 1010, 1 × 1011, 1 × 1012 viral particles). Safety, response and pharmacodynamics were evaluated. Sixteen patients with a variety of solid tumors were enrolled. IT of Telomelysin was well tolerated at all dose levels. Common grade 1 and 2 toxicities included injection site reactions (pain, induration) and systemic reactions (fever, chills). hTERT expression was demonstrated at biopsy in 9 of 12 patients. Viral DNA was transiently detected in plasma in 13 of 16 patients. Viral DNA was detectable in four patients in plasma or sputum at day 7 and 14 post-treatment despite below detectable levels at 24 h, suggesting viral replication. One patient had a partial response of the injected malignant lesion. Seven patients fulfilled Response Evaluation Criteria in Solid Tumors (RECIST) definition for stable disease at day 56 after treatment. Telomelysin was well tolerated. Evidence of antitumor activity was suggested." @default.
• W2039084800 created "2016-06-24" @default.
• W2039084800 creator A5029076256 @default.
• W2039084800 creator A5046995957 @default.
• W2039084800 creator A5054250864 @default.
• W2039084800 creator A5055054082 @default.
• W2039084800 creator A5060276623 @default.
• W2039084800 creator A5067526715 @default.
• W2039084800 creator A5067553211 @default.
• W2039084800 creator A5068717107 @default.
• W2039084800 creator A5069510259 @default.
• W2039084800 creator A5073374193 @default.
• W2039084800 creator A5075032781 @default.
• W2039084800 creator A5077484114 @default.
• W2039084800 creator A5084139812 @default.
• W2039084800 creator A5085425164 @default.
• W2039084800 creator A5088629605 @default.
• W2039084800 date "2010-02-01" @default.
• W2039084800 modified "2023-10-07" @default.
• W2039084800 title "A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors" @default.
• W2039084800 cites W1709060815 @default.
• W2039084800 cites W1965194293 @default.
• W2039084800 cites W1971397865 @default.
• W2039084800 cites W1976151688 @default.
• W2039084800 cites W1982222256 @default.
• W2039084800 cites W1985842299 @default.
• W2039084800 cites W1986213970 @default.
• W2039084800 cites W1986848545 @default.
• W2039084800 cites W1998128870 @default.
• W2039084800 cites W2005603741 @default.
• W2039084800 cites W2008776042 @default.
• W2039084800 cites W2011382333 @default.
• W2039084800 cites W2014601515 @default.
• W2039084800 cites W2016647287 @default.
• W2039084800 cites W2019013329 @default.
• W2039084800 cites W2022386076 @default.
• W2039084800 cites W2040976531 @default.
• W2039084800 cites W2042351268 @default.
• W2039084800 cites W2053390368 @default.
• W2039084800 cites W2054596841 @default.
• W2039084800 cites W2055477134 @default.
• W2039084800 cites W2065354528 @default.
• W2039084800 cites W2069264958 @default.
• W2039084800 cites W2081484258 @default.
• W2039084800 cites W2105005357 @default.
• W2039084800 cites W2109828337 @default.
• W2039084800 cites W2110275053 @default.
• W2039084800 cites W2110752622 @default.
• W2039084800 cites W2111950267 @default.
• W2039084800 cites W2114160100 @default.
• W2039084800 cites W2128023051 @default.
• W2039084800 cites W2136752442 @default.
• W2039084800 cites W2143446789 @default.
• W2039084800 cites W2144685993 @default.
• W2039084800 cites W2158691858 @default.
• W2039084800 cites W2170815810 @default.
• W2039084800 cites W2322171375 @default.
• W2039084800 cites W2332751481 @default.
• W2039084800 cites W2003632819 @default.
• W2039084800 doi "https://doi.org/10.1038/mt.2009.262" @default.
• W2039084800 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2839300" @default.
• W2039084800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19935775" @default.
• W2039084800 hasPublicationYear "2010" @default.
• W2039084800 type Work @default.
• W2039084800 sameAs 2039084800 @default.
• W2039084800 citedByCount "221" @default.
• W2039084800 countsByYear W20390848002012 @default.
• W2039084800 countsByYear W20390848002013 @default.
• W2039084800 countsByYear W20390848002014 @default.
• W2039084800 countsByYear W20390848002015 @default.
• W2039084800 countsByYear W20390848002016 @default.
• W2039084800 countsByYear W20390848002017 @default.
• W2039084800 countsByYear W20390848002018 @default.
• W2039084800 countsByYear W20390848002019 @default.
• W2039084800 countsByYear W20390848002020 @default.
• W2039084800 countsByYear W20390848002021 @default.
• W2039084800 countsByYear W20390848002022 @default.
• W2039084800 countsByYear W20390848002023 @default.
• W2039084800 crossrefType "journal-article" @default.
• W2039084800 hasAuthorship W2039084800A5029076256 @default.
• W2039084800 hasAuthorship W2039084800A5046995957 @default.
• W2039084800 hasAuthorship W2039084800A5054250864 @default.
• W2039084800 hasAuthorship W2039084800A5055054082 @default.
• W2039084800 hasAuthorship W2039084800A5060276623 @default.
• W2039084800 hasAuthorship W2039084800A5067526715 @default.
• W2039084800 hasAuthorship W2039084800A5067553211 @default.
• W2039084800 hasAuthorship W2039084800A5068717107 @default.
• W2039084800 hasAuthorship W2039084800A5069510259 @default.
• W2039084800 hasAuthorship W2039084800A5073374193 @default.
• W2039084800 hasAuthorship W2039084800A5075032781 @default.
• W2039084800 hasAuthorship W2039084800A5077484114 @default.
• W2039084800 hasAuthorship W2039084800A5084139812 @default.
• W2039084800 hasAuthorship W2039084800A5085425164 @default.
• W2039084800 hasAuthorship W2039084800A5088629605 @default.
• W2039084800 hasBestOaLocation W20390848001 @default.
• W2039084800 hasConcept C104317684 @default.
• W2039084800 hasConcept C111113717 @default.
• W2039084800 hasConcept C112705442 @default.

• next